<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02604537</url>
  </required_header>
  <id_info>
    <org_study_id>15060</org_study_id>
    <nct_id>NCT02604537</nct_id>
  </id_info>
  <brief_title>Celestone Versus Ketorolac Injection for the Treatment of DeQuervains Tenosyovitis</brief_title>
  <official_title>Celestone Versus Ketorolac Injection for the Treatment of DeQuervains Tenosyovitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OrthoCarolina Research Institute, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OrthoCarolina Research Institute, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if corticosteriod injection modifies the natural
      course of de Quervain tendinopathy compared to a toradol injection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2015</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual analog scale of pain with finklestein test</measure>
    <time_frame>6 weeks post injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual analog scale of pain with tenderness over tendon</measure>
    <time_frame>pre injection, 2 weeks post injection, 6 weeks post injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analog scale of pain on radial side of wrist</measure>
    <time_frame>pre injection, 2 weeks post injection, 6 weeks post injection, 3 months post injection, 6 month post injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Disabilities of the Arm, Shoulder, and Hand Score (DASH)</measure>
    <time_frame>pre injection, 2 weeks post injection, 6 weeks post injection, 3 months post injection, 6 months post injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Veterans-Rand 12 (VR-12)</measure>
    <time_frame>pre injection, 2 weeks post injection, 6 weeks post injection, 3 months post injection, 6 months post injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pinch Strength</measure>
    <time_frame>pre-injection, 2 weeks post injection, 6 weeks post injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grip Strength</measure>
    <time_frame>pre injection, 2 weeks post injection, 6 weeks post injection</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>DeQuervain Tendinopathy</condition>
  <arm_group>
    <arm_group_label>Celestone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 6 mg/ml Celestone OR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketorolac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 30 mg/ml of Ketoraloc</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celestone</intervention_name>
    <description>1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 6 mg/ml celestone OR</description>
    <arm_group_label>Celestone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 30 mg/ml of ketorolac</description>
    <arm_group_label>Ketorolac</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of deQuervain tendinopathy

          -  Understands the local language and is willing and able to follow the requirements of
             the protocol

          -  Understands the informed consent and signs the institutional review board/independent
             ethics committee (IRB/IEC) approved informed consent form

        Exclusion Criteria:

          -  Patients who have an allergy to lidocaine, celestone, or ketorolac, NSAIDS, or ASA

          -  Patients who have an adverse reaction to lidocaine, celestone, or ketorolac (such as
             severe elevation of blood sugars in diabetics that caused medical complication)

          -  Patients who have received a prior steriod injection within the past three months

          -  Patients who have had a prior ipsilateral surgery for De!uervains Tenosyovitis

          -  Patients that have a skin lesion at the location of injection (such as trauma, eczema,
             rash)

          -  Patients who have a current infection at the location of injection

          -  Patients who have had iontophoresis within three months

          -  Patients who are breast feeding, pregnant, or who plan to become pregnant in the next
             six months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Chadderdon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OrthoCarolina Research Institute, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susan Odum, PhD</last_name>
    <phone>704.323.2265</phone>
    <email>Susan.Odum@OrthoCarolina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>OrthoCarolina</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan M Odum, PhD</last_name>
      <phone>704-323-2265</phone>
      <email>Susan.Odum@OrthoCarolina.com</email>
    </contact>
    <investigator>
      <last_name>Christopher Chadderdon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2015</study_first_submitted>
  <study_first_submitted_qc>November 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2015</study_first_posted>
  <last_update_submitted>July 7, 2017</last_update_submitted>
  <last_update_submitted_qc>July 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tendinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>July 7, 2017</submitted>
    <returned>August 7, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

